Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$5.44
-0.22 (-3.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $491.6M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
272.0x
↑EV/EBITDA
13.3x
↑ROE
2.3%
↑Gross Margin
40.9%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.6%
FCF CAGR
-43.7%
FCF margin
2.8%
FCF / Net income
1.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.91B · net income $70.6M · FCF $80.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.91B | $2.91B | $3.22B | $3.78B | $3.69B |
| Net Income | $70.6M | $70.6M | $133.5M | $117.1M | $35.4M |
| EBITDA | $438.3M | $438.3M | $552.2M | $476.0M | $317.8M |
| EPS | 0.07 | 0.07 | 0.12 | 0.11 | 0.03 |
| Gross Margin | 40.9% | 40.9% | 45.4% | 46.4% | 49.1% |
| Operating Margin | 10.4% | 10.4% | 9.8% | 6.5% | 6.7% |
| Net Margin | 2.4% | 2.4% | 4.2% | 3.1% | 1.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | — | — | — |
| Current Ratio | 2.08 | 2.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $80.6M | $80.6M | $491.6M | $649.9M | $451.3M |
| Returns | |||||
| ROE | 2.3% | 2.3% | 4.4% | 4.0% | 1.2% |
| Valuation | |||||
| P/E | 272.00 | 272.00 | 33.85 | 46.26 | 140.31 |
| EV/EBITDA | 13.27 | 13.27 | 7.03 | 9.87 | 13.60 |
| P/B | 1.95 | 1.95 | 1.48 | 1.83 | 1.67 |
| Growth & Yield | |||||
| Revenue Growth | -9.6% | -9.6% | -15.0% | 2.5% | — |
| EPS Growth | -46.7% | -46.7% | 14.0% | 234.4% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
95.1%
EPS terminal req.
$0.48
Spread vs growth
-141.8%
5Y implied EPS CAGR
55.1%
EPS terminal req.
$0.58
Spread vs growth
-101.9%
10Y implied EPS CAGR
30.6%
EPS terminal req.
$0.94
Spread vs growth
-77.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.9%
Start / end P/E
34.3x → 83.7x
EPS bridge
0.12 → 0.07
Residual
-67.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.